Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc exhibits a positive outlook due to the demonstrated efficacy of its product candidate, lorundrostat, which has shown a placebo-adjusted blood pressure reduction exceeding 10 mmHg, a significant threshold that is likely to enhance prescriber interest. The robust and differentiated profile of lorundrostat in treating uncontrolled and resistant hypertension is emphasized by favorable results that stand out against Phase 3 competitor data, indicating a strong market potential. Furthermore, the anticipated near-term FDA feedback and the upcoming New Drug Application (NDA) submission add to the optimism surrounding the company's future prospects.

Bears say

Mineralys Therapeutics faces several fundamental challenges that contribute to a negative outlook on its stock. The risks identified include the potential failure of its product candidate, lorundrostat, to meet peak commercial revenue estimates due to limitations in market size, penetration rates, and pricing strategies. Additionally, the company may encounter difficulties in securing the necessary capital to fund ongoing operations and face hurdles related to the continued development and commercialization of its therapeutic programs.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.